JDRF consortium defines roadmap for testing potential links between gut microbes and type 1 diabetes One of the first questions a person or parent of a child diagnosed with type 1 diabetes (T1D) often asks is, “what caused this?” While we have learned a lot about T1D, we still do not have a simple answer […]
JDRF has a plan for creating a world without type 1 diabetes (T1D) that focuses on driving promising therapies through the R&D pipeline and into the hands of individuals with T1D. A critical step in progress along the pipeline is known as the translational research phase. The goal of translational research is to move research […]
Every day, JDRF leverages the expertise and innovation of distinguished researchers from across the globe to support research for life-changing treatments and ultimately a cure for type 1 diabetes (T1D). Our mission aims to serve everybody with T1D—at all ages and stages of the disease. Please enjoy reading about some of the most recent advances […]
People with type 1 diabetes may have a different makeup of gut flora—the microbes that live in the human digestive tract—compared to that found in people without the disease. By studying the collection of genes within this microbiome and assessing their functions, researchers hope to understand if, and how, an altered microbiome contributes to autoimmunity and the onset of type 1 diabetes.
By Richard Insel, M.D. As JDRF remains steadfast in its mission of curing type 1 diabetes, we are also committed to both improving treatments for individuals with the disease and preventing the disorder itself. Our treatment priorities include developing new drugs and devices that significantly improve glucose control, reduce the daily burden of living with […]
JDRF scientists have shed light on how regulatory T cells block the progress of diabetes. The findings highlight the important role of these cells in controlling autoimmunity and represent an important research advance that could be translated into therapies for people with type 1 diabetes.
To better understand the development of type 1 diabetes and to evaluate preventive interventions, researchers have initiated clinical studies in the relatives of individuals affected by the disease. A new clinical trial through TrialNet, a multi-center consortium sponsored by the National Institutes of Health, will be testing a drug’s efficacy in stopping the progression of […]